What is the Difference Between IgG4-SC and PSC?
At a Glance
The main difference between IgG4-related sclerosing cholangitis (IgG4-SC) and primary sclerosing cholangitis (PSC) is that IgG4-SC is an autoimmune condition that responds rapidly to steroid medications. Classic PSC generally does not respond to steroids and requires different medical management.
In this answer
4 sections
If your doctor is testing you for IgG4-related disease during a workup for Primary Sclerosing Cholangitis (PSC), they are trying to determine exactly which condition is causing the damage to your bile ducts. While IgG4-related sclerosing cholangitis (IgG4-SC) and classic PSC can look nearly identical on scans, they are fundamentally different diseases. The most important difference is that IgG4-SC is an autoimmune condition driven by specific antibodies that responds rapidly to steroid medications, whereas classic PSC generally does not respond to steroids and requires different medical management.
Why They Look So Similar on Scans
Both conditions cause severe inflammation and scarring that lead to strictures (narrowing) of the bile ducts [1][2]. Because of this, an MRI of your bile ducts (an MRCP scan) or an endoscopic procedure (ERCP) might look very similar regardless of which condition you have [1][3].
While a radiologist might notice that the strictures in IgG4-SC are sometimes smoother, longer, or more symmetric than those in classic PSC [4][5], imaging alone is usually not enough to confidently tell the two conditions apart without looking at your bloodwork, clinical symptoms, and overall health [1].
Key Differences in Diagnosis
Because they look similar on scans, doctors look for other clues to confirm which disease you have:
- Blood Tests: The defining feature of IgG4-SC is a significantly elevated level of immunoglobulin G4 (IgG4), a specific type of antibody, in the blood [6][1]. A level that is at least 1.25 times the upper limit of normal strongly points toward IgG4-SC [6][7]. However, it is important to know that a mildly elevated IgG4 level does not automatically mean you have IgG4-SC. Some people with classic PSC can also have elevated IgG4 on their lab reports, and occasionally people with IgG4-SC have normal levels [8][9]. This overlap is exactly why doctors often cannot rely on bloodwork alone.
- Associated Diseases: Classic PSC is very strongly linked to Inflammatory Bowel Disease (IBD), such as ulcerative colitis or Crohn’s disease [10][11]. In contrast, IgG4-SC is part of a systemic condition called “IgG4-related disease.” Instead of IBD, it is frequently accompanied by autoimmune pancreatitis (inflammation of the pancreas), gallbladder wall thickening, or swelling in other glands [10][12].
- Biopsies: In complex cases, doctors may need to take a small tissue sample (a biopsy) during an endoscopy to look for specific inflammatory cells under a microscope [8][13].
The Diagnostic “Steroid Trial”
Sometimes, even after blood tests, imaging, and biopsies, the diagnosis remains in a gray area. In these cases, your doctor might prescribe a short diagnostic trial of corticosteroids, such as prednisone, for a few weeks [4][14].
Because IgG4-SC responds exceptionally well and rapidly to glucocorticoid therapy, a quick and dramatic improvement in your liver enzyme blood tests and symptoms confirms the diagnosis [4][15].
If your numbers do not improve during this short trial, it tells your medical team that the condition is likely classic PSC or another variant. If that happens, your doctor will safely taper off the steroid medication and pivot back to standard PSC management.
Treatment and Long-Term Outlook
Getting the correct diagnosis is critical because the medical management and long-term outlook for the two conditions are completely different [4][2].
- Treating IgG4-SC: This condition is highly responsive to immune-suppressing medications [16]. Doctors use steroids to induce remission (rapidly bring the disease under control) [4][17]. Long-term remission is often managed with immunomodulators or therapies that target specific immune cells, allowing you to eventually taper off steroids [17][18].
- Treating PSC: Classic PSC generally does not respond to steroids or current immunosuppressive therapies [4][19]. It is a progressive disease managed by treating symptoms and complications as they arise, and there are currently no curative medical therapies outside of a liver transplant [16][19].
Overall, a diagnosis of IgG4-SC generally comes with a much better prognosis than classic PSC. Because it can be actively controlled with medication, patients with IgG4-SC have a significantly lower risk of progressing to cirrhosis (severe liver scarring) and do not carry the same high intrinsic risk for cholangiocarcinoma (bile duct cancer) as those with classic PSC [16][20].
Common questions in this guide
Why do doctors prescribe a steroid trial for suspected IgG4-SC?
Can I have elevated IgG4 levels but still have classic PSC?
Are the long-term outlooks different for IgG4-SC and classic PSC?
What other diseases are associated with IgG4-SC compared to PSC?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are my IgG4 levels elevated enough to strongly suspect IgG4-SC, or are they in a borderline range that could also happen with classic PSC?
- 2.Based on my imaging and bloodwork, do you think I am a good candidate for a diagnostic steroid trial?
- 3.Do my other organs, like my pancreas or gallbladder, show any signs of IgG4-related disease on my scans?
- 4.If we do a steroid trial and my liver numbers don't improve, what is our next step for confirming the diagnosis and managing my care?
- 5.If I do have IgG4-SC, what is the long-term plan for medications once we taper off the initial steroids?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (20)
- 1
Primary sclerosing cholangitis with increased immunoglobulin G4 levels: A case report.
Chen QL, Zhong R, Zhang XX, et al.
Medicine 2019; (98(50)):e18411 doi:10.1097/MD.0000000000018411.
PMID: 31852163 - 2
IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.
Tanaka A
Gut and liver 2019; (13(3)):300-307 doi:10.5009/gnl18085.
PMID: 30205418 - 3
Immunoglobulin G4-related sclerosing cholangitis.
Tanaka A
Journal of digestive diseases 2019; (20(7)):357-362 doi:10.1111/1751-2980.12789.
PMID: 31112324 - 4
An atypical case of isolated immunoglobulin G4-related sclerosing cholangitis with a cholangiogram resembling primary sclerosing cholangitis.
Takada Y, Ishikawa T, Yamao K, et al.
Clinical journal of gastroenterology 2024; (17(2)):338-344 doi:10.1007/s12328-023-01903-w.
PMID: 38170392 - 5
Difficulty in the diagnosis of isolated immunoglobulin G4-related sclerosing cholangitis.
Nakazawa T
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2019; (31(4)):391-392 doi:10.1111/den.13407.
PMID: 30920057 - 6
Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.
Lian M, Li B, Xiao X, et al.
Autoimmunity reviews 2017; (16(8)):875-882 doi:10.1016/j.autrev.2017.05.018.
PMID: 28564616 - 7
Diagnosis of isolated hilar-/extrahepatic-type IgG-4-related sclerosing cholangitis can be increased by improved recognition of this condition-A Japanese multicenter analysis.
Kubota K, Iwasaki E, Ishikawa T, et al.
Journal of hepato-biliary-pancreatic sciences 2024; (31(9)):647-657 doi:10.1002/jhbp.12053.
PMID: 39123289 - 8
Unexpected diagnosis: IgG4-related sclerosing cholangitis with normal serum IgG4 levels - Unraveling diagnostic and therapeutic challenges.
Barros S, Relvas L, Carvalho IM, et al.
Revista espanola de enfermedades digestivas 2025; (117(12)):761-762 doi:10.17235/reed.2024.10711/2024.
PMID: 39235183 - 9
Sump syndrome following hepaticojejunostomy: a case report of IgG4-related sclerosing cholangitis.
Ruan L, Chen W, Mei H
Frontiers in medicine 2025; (12()):1730125 doi:10.3389/fmed.2025.1730125.
PMID: 41601807 - 10
Journey to diagnosis: An unfinished exploration of IgG4-related sclerosing cholangitis.
Liang MX, Chen Y, He Y, He YH
World journal of clinical cases 2024; (12(33)):6608-6612 doi:10.12998/wjcc.v12.i33.6608.
PMID: 39600477 - 11
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS, Loftus EV, Raffals LE, et al.
Alimentary pharmacology & therapeutics 2018; (48(2)):190-195 doi:10.1111/apt.14829.
PMID: 29808485 - 12
Gallbladder wall thickening in patients with IgG4-related diseases, with special emphasis on IgG4-related cholecystitis.
Watanabe K, Kamisawa T, Chiba K, et al.
Scandinavian journal of gastroenterology 2021; (56(12)):1456-1461 doi:10.1080/00365521.2021.1971758.
PMID: 34486468 - 13
Histological features of autoimmune pancreatitis and IgG4-related sclerosing cholangitis with a correlation with imaging findings.
Notohara K
Journal of medical ultrasonics (2001) 2021; (48(4)):581-594 doi:10.1007/s10396-021-01148-5.
PMID: 34669070 - 14
Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.
Moon SH, Kim MH, Lee JK, et al.
Journal of gastroenterology 2017; (52(4)):483-493 doi:10.1007/s00535-016-1246-5.
PMID: 27470434 - 15
Budesonide with Low-Dose 6-Mercaptopurine as a Possible New Treatment for IgG4-Related Sclerosing Cholangitis and Systemic IgG4-Related Disease: A Case Report.
Gummlich BPM, Seif Amir Hosseini A, Schwörer H
The American journal of case reports 2022; (23()):e938272 doi:10.12659/AJCR.938272.
PMID: 36476942 - 16
The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
Ali AH, Bi Y, Machicado JD, et al.
Journal of gastroenterology 2020; (55(11)):1087-1097 doi:10.1007/s00535-020-01714-7.
PMID: 32770464 - 17
IgG4-Related Cholangitis.
Beuers U, Trampert DC
Seminars in liver disease 2025; (45(3)):381-396 doi:10.1055/a-2588-3875.
PMID: 40342085 - 18
IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse.
Ren X, Jin X, Liu L, Zhang M
Frontiers in medicine 2026; (13()):1732637 doi:10.3389/fmed.2026.1732637.
PMID: 41728618 - 19
Primary sclerosing cholangitis with moderately elevated serum-IgG4 - characterization and outcome of a distinct variant phenotype.
Zhou T, Lenzen H, Dold L, et al.
Liver international : official journal of the International Association for the Study of the Liver 2021; (41(12)):2924-2933 doi:10.1111/liv.15028.
PMID: 34328259 - 20
Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis.
Tanaka A, Tazuma S, Okazaki K, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017; (15(6)):920-926.e3 doi:10.1016/j.cgh.2016.12.038.
PMID: 28111336
This page is for informational purposes only and does not replace professional medical advice. Always consult your hepatologist or gastroenterologist regarding your specific diagnosis, bloodwork, and treatment plan.
Get notified when new evidence is published on Primary sclerosing cholangitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.